Randomised Phase 3 Study of Ivosidenib in IDH1-Mutant Chemotherapy-Refractory Cholangiocarcinoma
Year: 2019
Type: preprint
Study designs: Randomized Controlled Trial, Clinical Trial
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.3491912
Authors: Ghassan K. Abou-Alfa, Teresa Macarulla, Milind M. Javle, Robin K. Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V. Catenacci, Mitesh J. Borad, John Bridgewater, William P. Harris, Adrian G. Murphy, Do-Youn Oh, Jonathan Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin Wu, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew Zhu
Institutions: Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Hospital Universitario 12 De Octubre, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, University of Chicago, Mayo Clinic Hospital, University College London, University of Washington, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Seoul National University, Utah Cancer Specialists, Trinity College Dublin, University of Arizona, University of Southern California, USC Norris Comprehensive Cancer Center, Agios Pharmaceuticals (United States), The Christie Hospital, The Christie NHS Foundation Trust
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3173754236